AbbVie Inc (ABBV)vsUltragenyx (RARE)
ABBV
AbbVie Inc
$245.87
+0.89%
HEALTHCARE · Cap: $430.82B
RARE
Ultragenyx
$25.91
+0.35%
HEALTHCARE · Cap: $2.45B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9510% more annual revenue ($64.39B vs $670.00M). ABBV leads profitability with a 9.8% profit margin vs -90.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
RARE
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$245.87
$94.97 premium
Intrinsic value data unavailable for RARE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
ROE of -608.0% — below average capital efficiency
Revenue declined 2.2%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : RARE
The strongest argument for RARE centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : RARE
The primary concerns for RARE are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while RARE is a turnaround play — different risk/reward profiles.
RARE carries more volatility with a beta of 0.31 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 25/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ultragenyx
HEALTHCARE · BIOTECHNOLOGY · USA
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?